pregnancy management	290	NBK1435|NBK1419|NBK1152|NBK1264|NBK299311|NBK263441|NBK1193|NBK1519|NBK1108|NBK1267|NBK208534|NBK100238|NBK1159|NBK253404|NBK1131|NBK1241|NBK1426|NBK247162|NBK1363|NBK1151|NBK1503|NBK32534|NBK169615|NBK1322|NBK424403|NBK1517|NBK1212|NBK284774|NBK1500|NBK99168|NBK1171|NBK246980|NBK32533|NBK1328|NBK326661|NBK1513|NBK25565|NBK1293|NBK1391|NBK5313|NBK84551|NBK154652|NBK1250|NBK1186|NBK1259|NBK99496|NBK5188|NBK84550|NBK52917|NBK1168|NBK45014|NBK1205|NBK1285|NBK201366|NBK1468|NBK1340|NBK1342|NBK131811|NBK7046|NBK1527|NBK1253|NBK1458|NBK1400|NBK1409|NBK1289|NBK1533|NBK1474|NBK1674|NBK1309|NBK7047|NBK1350|NBK22301|NBK1447|NBK1534|NBK1508|NBK1491|NBK258640|NBK1492|NBK25442|NBK1501|NBK1157|NBK1304|NBK1125|NBK1369|NBK1306|NBK1436|NBK1244|NBK1279|NBK1494|NBK1462|NBK54467|NBK190102|NBK100826|NBK121284|NBK1163|NBK1401|NBK1345|NBK1180|NBK7050|NBK114458|NBK2534|NBK1227|NBK1543|NBK1673|NBK1281|NBK1459|NBK1443|NBK253403|NBK1518|NBK1269|NBK1318|NBK1523|NBK1481|NBK1312|NBK1261|NBK26372|NBK1344|NBK5941|NBK55061|NBK114807|NBK1529|NBK1404|NBK1495|NBK1440|NBK1423|NBK333439|NBK1139|NBK97260|NBK1351|NBK1375|NBK25507|NBK1444|NBK100241|NBK185330|NBK1395|NBK1211|NBK1524|NBK1111|NBK1338|NBK1287|NBK3789|NBK1509|NBK1367|NBK1768|NBK53700|NBK1496|NBK174884|NBK1477|NBK1472|NBK190103|NBK1675|NBK97965|NBK1170|NBK1405|NBK1478|NBK1469|NBK201978|NBK349072|NBK1484|NBK43417|NBK1457|NBK1383|NBK1313|NBK1420|NBK1311|NBK1133|NBK1308|NBK343782|NBK1335|NBK1424|NBK274564|NBK1356|NBK1354|NBK84258|NBK61984|NBK1233|NBK1257|NBK1520|NBK214367|NBK1499|NBK1146|NBK1239|NBK1828|NBK1231|NBK1290|NBK373578|NBK1162|NBK1319|NBK1128|NBK1422|NBK2689|NBK1355|NBK1165|NBK1132|NBK1177|NBK1288|NBK368475|NBK1109|NBK1201|NBK1357|NBK185066|NBK1331|NBK1370|NBK1166|NBK1232|NBK1188|NBK1295|NBK1427|NBK154378|NBK447152|NBK1451|NBK1548|NBK9673|NBK1280|NBK1122|NBK6852|NBK1486|NBK395975|NBK1283|NBK316514|NBK65707|NBK1465|NBK26472|NBK1246|NBK1460|NBK1504|NBK1221|NBK247161|NBK143129|NBK196157|NBK1485|NBK327267|NBK1229|NBK92946|NBK1487|NBK1148|NBK1113|NBK1115|NBK1353|NBK299312|NBK83985|NBK268648|NBK114805|NBK1129|NBK83297|NBK435692|NBK1175|NBK1225|NBK1438|NBK1140|NBK1256|NBK63582|NBK1756|NBK201365|NBK1377|NBK1143|NBK1310|NBK1479|NBK45978|NBK8828|NBK304122|NBK131810|NBK1379|NBK23758|NBK274566|NBK1366|NBK1349|NBK26373|NBK1103|NBK1282|NBK1515|NBK154138|NBK1341|NBK1463|NBK6816|NBK1967|NBK1271|NBK7014|NBK447258|NBK1178|NBK148820|NBK1514|NBK4144|NBK1249|NBK1512|NBK1531|NBK1112|NBK1213|NBK1397|NBK20221	
evaluations can include:	50	NBK1435|NBK1419|NBK1493|NBK1483|NBK355754|NBK1454|NBK1151|NBK1380|NBK1394|NBK22925|NBK1293|NBK1332|NBK1250|NBK84550|NBK1168|NBK1340|NBK1527|NBK3794|NBK1458|NBK1400|NBK269029|NBK22301|NBK1436|NBK1494|NBK1292|NBK1364|NBK1261|NBK1111|NBK1334|NBK1308|NBK1257|NBK1179|NBK148668|NBK368475|NBK185066|NBK154378|NBK447152|NBK65707|NBK1326|NBK1504|NBK1452|NBK1103|NBK1220|NBK1515|NBK1265|NBK3821|NBK1514|NBK1531|NBK1112|NBK1453	
evaluations include:	9	NBK154652|NBK7047|NBK1312|NBK100241|NBK1973|NBK1353|NBK1437|NBK1341|NBK1271	
mothertobaby	5	NBK1517|NBK447152|NBK65707|NBK1515|NBK1512	
evaluations can include the following:	5	NBK99496|NBK100826|NBK1673|NBK395975|NBK1512	
use of antiepileptic medication during pregnancy reduces this risk	4	NBK1293|NBK1491|NBK201978|NBK1465	
search clinicaltrials	3	NBK1419|NBK169431|NBK1146	
see mothertobaby for further information on medication use during pregnancy	3	NBK1108|NBK1308|NBK1465	
org	3	NBK1517|NBK447152|NBK65707	
therapies under investigation	2	NBK1419|NBK169431	
other	2	NBK1419|NBK169431	
males	2	NBK1207|NBK1292	
females	2	NBK1207|NBK1292	
molecular genetic testing	2	NBK1207|NBK395975	
identification of at-risk relatives	2	NBK1404|NBK1495	
early determination of the genetic status of males at risk	2	NBK1404|NBK1495	
determination of genetic status of females at risk	2	NBK1404|NBK1495	
obstetric issues	2	NBK1404|NBK1495	
newborn males	2	NBK1404|NBK1495	
cys282tyr	2	NBK1440|NBK1440	
particularly important are:	2	NBK53700|NBK1356	
240 (170)	2	NBK174884|NBK174884	
a parent, sib, or child	2	NBK174884|NBK174884	
first-degree relatives share about half of their genes	2	NBK174884|NBK174884	
a first cousin, great-grandparent, or great-grandchild	2	NBK174884|NBK174884	
during pregnancy	2	NBK174884|NBK1504	
see www	2	NBK1515|NBK1512	
monitoring for these possible complications is recommended	1	NBK1435	
the characteristic urinary steroid profile:	1	NBK1419	
significantly elevated metabolites associated with:	1	NBK1419	
fertility may be a concern	1	NBK1419	
no reports describe reproduction in individuals with pord	1	NBK1419	
hepatic drug metabolism	1	NBK1419	
the common pathogenic variant p	1	NBK1419	
stress should be minimized by providing good analgesia	1	NBK1193	
urinalysis	1	NBK1207	
a single urinalysis is sufficient in a male	1	NBK1207	
relatives who have the family-specific pathogenic variant should:	1	NBK1108	
undergo alps-specific evaluations at initial diagnosis (e	1	NBK1108	
, lymphoma) become apparent (see surveillance)	1	NBK1108	
severe dyslipidemia	1	NBK1267	
and hyperglycemia	1	NBK1267	
intensive multidisciplinary surveillance of any pregnancy would be mandatory	1	NBK1267	
leu167del variant	1	NBK208534	
if the apoe p	1	NBK208534	
a woman with the apoe p	1	NBK208534	
they are usually identified during family screening	1	NBK100238	
plasma quantitative amino acid analysis	1	NBK1159	
analysis of enzymatic activity in red blood cells	1	NBK1159	
all pregnancies had a good outcome	1	NBK253404	
peripartum intensive monitoring is advised	1	NBK253404	
medication-associated risks to the fetus	1	NBK253404	
, a beta-blocker) prior to conception	1	NBK253404	
ecg, with consideration of signal-averaged electrocardiogram	1	NBK1131	
echocardiogram	1	NBK1131	
holter monitoring	1	NBK1131	
cardiac mri	1	NBK1131	
however, prenatal physiotherapy may be indicated	1	NBK1503	
affected women should continue biotin and thiamine therapy during pregnancy	1	NBK169615	
an optimal prenatal dose has not been determined	1	NBK1322	
pregnancy may increase the risk of diabetic decompensation	1	NBK1212	
for an affected mother	1	NBK284774	
no pregnancy manaagement issues are known	1	NBK284774	
for an affected child	1	NBK284774	
no special management is required during pregnancy	1	NBK284774	
pregnant females with classic 21-ohd cah	1	NBK1171	
polyhydramnios	1	NBK246980	
the cause of polyhydramnios is unknown	1	NBK246980	
macrosomia	1	NBK246980	
molecular genetic testing for the causative contiguous gene deletion	1	NBK22925	
otologic examination and audiologic assessment	1	NBK22925	
0 mg im, folic acid 5	1	NBK1328	
of the 16 women, hemorrhage occured in ten	1	NBK1293	
6% compared with 1	1	NBK1293	
see malignant hyperthermia susceptibility for more details	1	NBK1391	
deterioration during pregnancy may precipitate preterm delivery	1	NBK1250	
mode of delivery is based on usual obstetric indications	1	NBK1250	
data regarding teratogenicity of itraconazole are limited	1	NBK99496	
the infants were normal	1	NBK5188	
early diagnosis of relatives (i	1	NBK84550	
completely asymptomatic individuals need not be tested	1	NBK84550	
no issues are known	1	NBK84550	
however, experience is limited	1	NBK84550	
females with ciss may conceive normally	1	NBK52917	
no complications during pregnancy have been reported to date	1	NBK52917	
the prescription of clonidine should not be discontinued abruptly	1	NBK52917	
data on pregnancies in cms are limited	1	NBK1168	
trpv4-associated neuromuscular disorders	1	NBK201366	
trpv4-associated skeletal dysplasias	1	NBK201366	
no specific pregnancy management recommendations have been published	1	NBK1468	
the symptoms of cmt can worsen during pregnancy	1	NBK1340	
in particular: cramps, subjective sensitivity (e	1	NBK1340	
, paresthesias), difficulty walking, and fatigue	1	NBK1340	
no obvious effect has been observed	1	NBK169431	
acute fatty liver of pregnancy	1	NBK1253	
maternal liver disease	1	NBK1253	
it is appropriate to evaluate relatives at risk (e	1	NBK1400	
treatment with chenodeoxycholic acid should not be interrupted during pregnancy	1	NBK1409	
otherwise serial ancs can be evaluated	1	NBK1533	
other findings included:	1	NBK1533	
dose adjustment may also be required post partum	1	NBK1474	
pregnancy management for heterozygous females	1	NBK1119	
, coronary artery disease)	1	NBK1674	
, left ventricular enlargement but normal function	1	NBK1674	
in most cases, pregnancy is contraindicated in dcm	1	NBK1309	
evaluations may include:	1	NBK1209	
consideration of other testing (e	1	NBK7047	
during pregnancy the maternal hemoglobin level must be monitored	1	NBK7047	
intrauterine growth retardation	1	NBK7047	
preeclampsia	1	NBK7047	
retroplacental hematoma	1	NBK7047	
in utero fetal death	1	NBK7047	
preterm delivery	1	NBK7047	
telomere length testing	1	NBK22301	
they should be followed closely by a perinatologist	1	NBK22301	
recommendations vary by underlying genetic mechanism:	1	NBK1534	
two women reported mild deterioration of dystonia	1	NBK1508	
an increase in dose was required in one	1	NBK1508	
see mothertobaby	1	NBK1491	
org for further information on medication use during pregnancy	1	NBK1491	
2-q13	1	NBK367946	
caesarean section delivery may be required	1	NBK1436	
labor and delivery may progress very rapidly	1	NBK1279	
there is no clear advantage to vaginal vs	1	NBK1279	
cesarean delivery	1	NBK1279	
delivery should be performed in a medical center	1	NBK1462	
pregnancy is not complicated by epp	1	NBK100826	
there is no information on pregnancy management in xlp	1	NBK121284	
measure Î±-gal a enzyme activity	1	NBK1292	
however, the indications for family testing are unresolved	1	NBK1368	
recommended genetic testing for at-risk family members	1	NBK1345	
pregnancy/fertility/hormone use	1	NBK1345	
visceral pain related to contractions during labor is perceived normally	1	NBK1180	
therefor, analgesia should be provided	1	NBK1180	
this is especially important when the p	1	NBK1227	
poncz & cohen 1996	1	NBK1673	
min et al 2008	1	NBK1673	
goldman, personal communication to author]	1	NBK1673	
diagnostic evaluations can include:	1	NBK51671	
molecular genetic testing for the familial gata1 pathogenic variant	1	NBK1364	
effect of anticonvulsants on hormonal methods of birth control	1	NBK1318	
effects of anticonvulsants on conception	1	NBK1318	
effect of pregnancy on anticonvulsant metabolism	1	NBK1318	
effect of pregnancy on maternal seizure control	1	NBK1318	
renal anomalies	1	NBK1523	
skeletal differences such as club foot and craniosynostosis	1	NBK1523	
and umbilical and inguinal hernia	1	NBK1523	
baseline ultrasound of liver and kidneys prior to pregnancy	1	NBK1312	
consideration of referral to high-risk obstetrician	1	NBK1312	
metabolic control should be followed closely throughout the pregnancy	1	NBK1312	
abdominal ultrasound should be performed every six to 12 weeks	1	NBK1312	
the effect of pregnancy on inducing acute attacks is unpredictable	1	NBK114807	
in general, serious problems during pregnancy are unusual	1	NBK114807	
if the female is symptomatic (i	1	NBK1404	
range: 15%-50%)	1	NBK1495	
the following strategy is appropriate:	1	NBK1440	
perform iron studies (i	1	NBK1440	
no guidelines exist	1	NBK1440	
common practice is to withhold phlebotomy during pregnancy	1	NBK1440	
coli sepsis and pulmonary edema	1	NBK333439	
testing of populations at risk	1	NBK1139	
cessation of prophylactic antimicrobials is often advised during pregnancy	1	NBK25507	
ideally cancer screening exams would be planned around a pregnancy	1	NBK1211	
hyperpyrexia and its potential complications, including febrile seizures	1	NBK1769	
, first 28 days of life)	1	NBK1769	
no monitoring is needed for:	1	NBK1367	
8%) and preeclampsia (7	1	NBK1367	
7%)	1	NBK1367	
children because of their increased risk for anemia	1	NBK53700	
measurement of ldl-c level	1	NBK174884	
table 4	1	NBK174884	
degree of relatedness to an affected individual	1	NBK174884	
first degreeÂ 1	1	NBK174884	
second degreeÂ 2	1	NBK174884	
third degreeÂ 3	1	NBK174884	
cholesterol levels	1	NBK174884	
total cholesterol (ldl cholesterol) in mg/dl	1	NBK174884	
age	1	NBK174884	
<20	1	NBK174884	
220 (155)	1	NBK174884	
230 (165)	1	NBK174884	
20-29	1	NBK174884	
250 (180)	1	NBK174884	
260 (185)	1	NBK174884	
30-39	1	NBK174884	
270 (190)	1	NBK174884	
280 (200)	1	NBK174884	
290 (210)	1	NBK174884	
40+	1	NBK174884	
290 (205)	1	NBK174884	
300 (215)	1	NBK174884	
310 (225)	1	NBK174884	
statins are contraindicated during pregnancy	1	NBK174884	
pharmacologic treatment	1	NBK174884	
statins are contraindicated in pregnancy due to concerns for teratogenicity	1	NBK174884	
nursing mothers should not take statins	1	NBK174884	
ldl apheresis is also occasionally used	1	NBK174884	
regarding other agents:	1	NBK174884	
pcsk9 inhibitors	1	NBK174884	
use during pregnancy has not been well studied	1	NBK174884	
ezetimibe	1	NBK174884	
use during human pregnancy has not been well studied	1	NBK174884	
niacin	1	NBK174884	
higher doses have been associated with toxicity	1	NBK174884	
risks during delivery include cephalopelvic disproportion	1	NBK190103	
pregnancy in women with parkinson disease is a rare event	1	NBK1478	
see hereditary hemorrhagic telangiectasia, pregnancy management	1	NBK1469	
see mothertobaby for more information on medication use during pregnancy	1	NBK201978	
edema may be exacerbated during pregnancy	1	NBK1457	
if the ptpn11, raf1,	1	NBK1383	
some carrier females develop gout in later years	1	NBK1149	
if the causal tgfbr1,	1	NBK1133	
pregnancy can be dangerous for women with lds	1	NBK1133	
it is appropriate to evaluate at-risk sibs during infancy	1	NBK1308	
measurement of plasma triglyceride concentration	1	NBK1308	
affected mother	1	NBK343782	
affected fetus	1	NBK343782	
0 cm	1	NBK1335	
at a root dimension <5	1	NBK1335	
0cm) before becoming pregnant	1	NBK1335	
pregnant women who have mcad deficiency must avoid catabolism	1	NBK1424	
for the purpose of early diagnosis and treatment	1	NBK153723	
for the purpose of kidney donation	1	NBK153723	
no pregnancy issues are particular to adtkd-umod	1	NBK1356	
thus, no particular recommendations can be made	1	NBK1354	
no prenatal or perinatal neurologic manifestations of mls are known	1	NBK1354	
using genomic testing that will detect the 15q13	1	NBK50780	
close monitoring for intrauterine growth retardation is warranted	1	NBK84258	
using genomic testing that will detect the 1q21	1	NBK52787	
3 microdeletion	1	NBK61984	
infertility may preclude pregnancy in some affected individuals	1	NBK1233	
men 2a	1	NBK1257	
fmtc	1	NBK1257	
men 2b	1	NBK1257	
albumin-corrected calcium or ionized calcium for hyperparathyroidism	1	NBK1257	
, cardiac and renal defects)	1	NBK214367	
fetal monitoring should follow standard guidelines	1	NBK1146	
continuous epidural analgesia is highly recommended for labor and delivery	1	NBK1146	
therapies under investigations	1	NBK1146	
ultrasound abnormalities are not present in all affected pregnancies	1	NBK1828	
abnormal presentation of an affected fetus may complicate delivery	1	NBK1290	
no information on pregnancy management and outcomes is available	1	NBK373578	
penetrance rates, however, are not known	1	NBK1425	
the post-partum period is dangerous for the mother	1	NBK1319	
evaluation includes targeted molecular genetic testing for the fgfr3 c	1	NBK1415	
749c>g pathogenic variant	1	NBK1415	
evaluation for placenta previa	1	NBK1165	
otherwise, monitor renal findings (i	1	NBK1132	
additional testing is not indicated	1	NBK1232	
the first pregnancy ended in miscarriage at 19 weeks	1	NBK447152	
, pre-eclampsia)	1	NBK1548	
no treatment for the condition is available	1	NBK9673	
birth is usually normal and uncomplicated	1	NBK9673	
fetal akinesia often causes congenital contractures	1	NBK9673	
clonus persists after birth and is usually severe	1	NBK9673	
absence of respiratory movement necessitates mechanical support at birth	1	NBK9673	
if not, treatment can be withdrawn	1	NBK1486	
, avoidance of unattended swimming)	1	NBK1537	
see treatment of manifestations	1	NBK242617	
possible those who would benefit from initiation of treatment	1	NBK1230	
1994a, schwartz et al 1994b]	1	NBK1230	
it is recommended that every five years, asymptomatic	1	NBK1230	
standardized questionnaire to assess the presence of respiratory	1	NBK1230	
symptoms	1	NBK1230	
family members are considered to have a positive screening	1	NBK1230	
evaluation (i	1	NBK1230	
, to possibly have pulmonary fibrosis) if they	1	NBK1230	
family members	1	NBK1230	
radiologic and histopathologic abnormalities suggestive of possible	1	NBK1230	
early interstitial lung disease	1	NBK1230	
it is unknown if these findings would	1	NBK1230	
become symptomatic fpf in the subjects	1	NBK1230	
see genetic	1	NBK1230	
genetic counseling purposes	1	NBK1230	
if the epor pathogenic variant in the family is known	1	NBK395975	
if no pathogenic variant has been identified in the family	1	NBK395975	
asymptomatic individuals:	1	NBK1283	
can be monitored periodically for renal function and urinary oxalate	1	NBK1283	
should maintain adequate hydration and avoid high-oxalate foods	1	NBK1283	
in addition:	1	NBK1283	
for those with the pathogenic variant p	1	NBK1283	
gly170arg or p	1	NBK1283	
phe152ile, pyridoxine should be supplemented	1	NBK1283	
, heterozygous for one hoga1 pathogenic variant)	1	NBK316514	
adequate fluid intake should be maintained throughout the pregnancy	1	NBK316514	
measurement of serum potassium concentration and blood pressure	1	NBK65707	
early diagnosis and treatment	1	NBK1266	
surveillance as outlined in surveillance	1	NBK1266	
see related genetic counseling issues	1	NBK1490	
presymptomatic diagnosis:	1	NBK1246	
permits early detection and treatment of complications and associated disorders	1	NBK1246	
reassures those found to be unaffected	1	NBK1246	
the literature on pregnancy and pkd is limited	1	NBK1246	
women with pah deficiency	1	NBK1504	
preconception	1	NBK1504	
assessment of early osteopenia risk	1	NBK1504	
discontinuation of lnaa treatment	1	NBK1504	
post partum	1	NBK1504	
provide coordinated care in the post-partum period	1	NBK1504	
spasticity generally does not change significantly with pregnancy	1	NBK247161	
pregnancy is generally not complicated by f-pct	1	NBK143129	
newer effective therapies may decrease the risk	1	NBK1485	
and an audiology evaluation	1	NBK1973	
see published guidelines/consensus statements	1	NBK1148	
prophylactic anticoagulation during pregnancy:	1	NBK1148	
is recommended for all women:	1	NBK1148	
should be considered for:	1	NBK1148	
all women received a course of postpartum anticoagulation	1	NBK1148	
all asymptomatic homozygous women	1	NBK1148	
prevention of pregnancy loss	1	NBK1148	
trialregister	1	NBK1148	
nl, ntr 3361)	1	NBK1148	
studies suggesting that prophylactic anticoagulation improves pregnancy outcome:	1	NBK1148	
5% and 15	1	NBK1148	
other pregnancy complications	1	NBK1148	
young or uncooperative children may require examination under anesthesia	1	NBK1452	
recommended doses during pregnancy are 10 mg/kg/day	1	NBK299312	
evaluation can be accomplished by:	1	NBK83985	
pregnancy in affected women appears to be generally uncomplicated	1	NBK268648	
that has documented lqts	1	NBK1129	
in which evaluation for lqts has not been performed	1	NBK1129	
or both of the following:	1	NBK1129	
weight gain during pregnancy can further impair gait ataxia	1	NBK1225	
affected women may be on medications (e	1	NBK1438	
, antiepileptics) to control the symptoms of sca17	1	NBK1438	
successful pregnancies have occurred in women with short syndrome	1	NBK201365	
if present, diabetes mellitus is managed as appropriate	1	NBK201365	
the following are appropriate:	1	NBK1228	
clinical appraisal and lateral skull radiograph as indicated	1	NBK1228	
no pregnancy complications have been reported	1	NBK1379	
almost all develop thrombocytopenia during pregnancy	1	NBK23758	
it can be addressed on three levels:	1	NBK1366	
maternal	1	NBK1366	
avoidance of emergency c-section for fetal distress	1	NBK1366	
fetal	1	NBK1366	
familial	1	NBK1366	
org for more information on medication exposure during pregnancy	1	NBK1515	
audiology	1	NBK1341	
abr, dpoae	1	NBK1341	
such test results need to be interpreted with caution	1	NBK1463	
, vhl syndrome or other hereditary disorder)	1	NBK1463	
during pregnancy, affected women may develop small new lesions	1	NBK1967	
penetrance is complete (i	1	NBK1271	
delayed, secondary postpartum bleeding may be a problem	1	NBK7014	
wolfram syndrome	1	NBK4144	
low-frequency sensorineural hearing loss (lfsnhl)	1	NBK4144	
pregnancies in women with ws are high risk	1	NBK1249	
zinc has been used effectively during pregnancy	1	NBK1512	
org for more information on medication use during pregnancy	1	NBK1512	
there are no other special recommendations for pregnancy management	1	NBK1112	
regular monitoring with pregnancy tests is indicated	1	NBK1397	
